HK1031399A1 - Process for synthesizing cox-2 inhibitors. - Google Patents

Process for synthesizing cox-2 inhibitors.

Info

Publication number
HK1031399A1
HK1031399A1 HK01102195A HK01102195A HK1031399A1 HK 1031399 A1 HK1031399 A1 HK 1031399A1 HK 01102195 A HK01102195 A HK 01102195A HK 01102195 A HK01102195 A HK 01102195A HK 1031399 A1 HK1031399 A1 HK 1031399A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
cox
synthesizing
synthesizing cox
Prior art date
Application number
HK01102195A
Other languages
English (en)
Inventor
Edward G Corley
Robert D Larsen
Kai Rossen
Ian W Davies
Philip J Pye
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK1031399A1 publication Critical patent/HK1031399A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK01102195A 1998-04-24 2001-03-26 Process for synthesizing cox-2 inhibitors. HK1031399A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15
PCT/US1999/008645 WO1999055830A2 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (1)

Publication Number Publication Date
HK1031399A1 true HK1031399A1 (en) 2001-06-15

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102195A HK1031399A1 (en) 1998-04-24 2001-03-26 Process for synthesizing cox-2 inhibitors.

Country Status (28)

Country Link
US (2) US6040319A (xx)
EP (1) EP1071745B1 (xx)
JP (2) JP3325264B2 (xx)
KR (1) KR100414998B1 (xx)
CN (1) CN1178658C (xx)
AR (1) AR015279A1 (xx)
AT (1) ATE272613T1 (xx)
AU (1) AU759469B2 (xx)
BR (2) BR9909844B1 (xx)
CA (1) CA2329193C (xx)
CZ (1) CZ292515B6 (xx)
DE (1) DE69919151T2 (xx)
DK (1) DK1071745T3 (xx)
EA (1) EA002975B1 (xx)
ES (1) ES2226378T3 (xx)
HK (1) HK1031399A1 (xx)
HR (1) HRP20000722B1 (xx)
HU (1) HU227627B1 (xx)
IL (2) IL139127A0 (xx)
NZ (1) NZ507597A (xx)
PL (1) PL193248B1 (xx)
PT (1) PT1071745E (xx)
RS (1) RS49945B (xx)
SI (1) SI1071745T1 (xx)
SK (1) SK284805B6 (xx)
TW (1) TW474934B (xx)
UA (1) UA57143C2 (xx)
WO (1) WO1999055830A2 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
ATE253559T1 (de) * 1999-01-14 2003-11-15 Lonza Ag Verfahren zur herstellung von 1-(6-methylpyridin- 3-yl)-2- 4-(methylsulfonyl phenyl)ethanon
MXPA01007169A (es) 1999-01-14 2003-06-06 Lonza Ag 1-(6-metilpiridin-3-il)-2-(4-(metilsulfonil)fenil)etanona y metodo para su elaboracion.
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
DK1248618T3 (da) * 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−2阻害剤組成物
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) * 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
EP1784179A4 (en) 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP2479166B1 (en) 2009-02-27 2014-08-20 Cadila Healthcare Limited A process for the preparation of etoricoxib
EP2582690B1 (en) 2010-06-16 2018-07-25 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
MY163379A (en) 2010-11-15 2017-09-15 Virdev Intermediates Pvt Ltd A process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2714676T1 (sl) 2011-05-27 2019-06-28 Farma Grs, D.O.O. Postopek za pripravo polimorfne oblike I etorikoksiba
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
WO2013144977A2 (en) 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
HU227732B1 (en) * 1996-07-18 2012-01-30 Merck Frosst Canada Ltd Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
KR20010042941A (ko) 2001-05-25
CA2329193A1 (en) 1999-11-04
PL344108A1 (en) 2001-09-24
EP1071745A2 (en) 2001-01-31
CZ292515B6 (cs) 2003-10-15
US6252116B1 (en) 2001-06-26
ATE272613T1 (de) 2004-08-15
EA002975B1 (ru) 2002-12-26
HU227627B1 (en) 2011-10-28
PT1071745E (pt) 2004-11-30
DK1071745T3 (da) 2004-11-29
AU759469B2 (en) 2003-04-17
HRP20000722B1 (en) 2009-07-31
HRP20000722A2 (en) 2001-06-30
DE69919151T2 (de) 2005-07-28
YU64100A (sh) 2002-11-15
IL139127A (en) 2006-07-05
CA2329193C (en) 2007-01-23
BRPI9917739B1 (pt) 2016-05-03
JP3325264B2 (ja) 2002-09-17
JP2003040852A (ja) 2003-02-13
EP1071745B1 (en) 2004-08-04
EP1071745A4 (en) 2002-05-15
IL139127A0 (en) 2001-11-25
PL193248B1 (pl) 2007-01-31
JP2002513035A (ja) 2002-05-08
BR9909844B1 (pt) 2010-10-19
HUP0101407A3 (en) 2002-12-28
UA57143C2 (uk) 2003-06-16
HUP0101407A2 (hu) 2001-09-28
DE69919151D1 (de) 2004-09-09
SK284805B6 (sk) 2005-11-03
EA200001102A1 (ru) 2001-04-23
CN1306425A (zh) 2001-08-01
US6040319A (en) 2000-03-21
CN1178658C (zh) 2004-12-08
CZ20003940A3 (en) 2001-06-13
WO1999055830A2 (en) 1999-11-04
KR100414998B1 (ko) 2004-01-13
TW474934B (en) 2002-02-01
WO1999055830A3 (en) 1999-12-29
JP3834263B2 (ja) 2006-10-18
AR015279A1 (es) 2001-04-18
BRPI9917739B8 (pt) 2021-05-25
SK15892000A3 (sk) 2001-07-10
AU3655799A (en) 1999-11-16
ES2226378T3 (es) 2005-03-16
BR9909844A (pt) 2001-04-03
NZ507597A (en) 2004-02-27
RS49945B (sr) 2008-09-29
SI1071745T1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
HK1031399A1 (en) Process for synthesizing cox-2 inhibitors.
ZA997866B (en) Method for providing refrigeration.
ZA200203293B (en) Method for synthesizing the nucleic acid.
ZA200001333B (en) Method for communicating information.
IL138821A (en) Method for unambigous range estimation
AU5660399A (en) An apparatus for performing animal related operations
HK1052702A1 (en) Method for the preparation of 5-carboxyphthalide.
ZA200110514B (en) Process for the extraction of copper.
AU3444899A (en) Method for the rapid determination of bacteria
EP1059760A4 (en) BLOCK ENCRYPTION OF DISCRETE DATA
AU5867901A (en) Method for detecting tumors
AU5041099A (en) Hydroformylation process
MX225445B (es) Metodo y produccion de n-fosfonometilglicina.
HUP9901733A3 (en) Method for transmitting data
AU1810399A (en) Method for synthesizing
HK1044780A1 (en) Method for producing cyclo-)asp-dphe-nmeval-arg-gly).
HUP0102016A3 (en) Method for copperplating substrates
ZA996792B (en) Method for producing stainless steel.
HUP0103002A3 (en) New process for obtaining 17betha-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids
HUP0102296A3 (en) Method for chlorinating ketones
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU7105800A (en) Process for synthesizing isoxazolidines
MXPA01001471A (es) Nuevo proceso para la sintesis de exoquelinas.
AU5541199A (en) An apparatus for performing animal related operations
AU2378100A (en) Process for making an emulsion

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140420